Abstract: One aspect of the present disclosure is a pharmaceutical composition which includes (R)—N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.

Abstract: An apparatus and method for manufacturing a grilled seaweed includes the apparatus comprising a grilling unit having a first housing with a first inlet opening and a first outlet opening which communicate with each other; a first conveyor for transferring a sheet of seaweed from the first inlet opening to the first outlet opening; a first heating source installed over the first conveyor to discharge a flame onto a top surface of the seaweed being transferred by the first conveyor; and a second heating source installed on both sides of a lower portion of the first conveyor to apply a flame onto a bottom surface of the seaweed being transferred by the first conveyor.

Abstract: Disclosed in this specification is a composition comprising polymer hyaluronic acid nanoparticles. In the present disclosure, the polymer hyaluronic acid is micronized to facilitate skin penetration without depolymerization of the polymer hyaluronic acid, and may be stably comprised in a formulation. In addition, the micronized polymer hyaluronic acid comprised in the composition of the present disclosure penetrates the skin and then is neutralized to pH of the skin and expanded in size again, which can provide excellent benefits for moisturizing the skin and improving skin elasticity.

Abstract: The present invention provides a recombinant exosome and uses thereof. More particularly, the present invention provides a recombinant exosome wherein a phagocytosis promoting protein is presented on the surface of the exosome.

Abstract: Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

Abstract: The present disclosure relates to a healable superplastic amorphous alloy, and specifically, to a healable superplastic amorphous alloy capable of exhibiting superplastic behavior and unique healable behavior by maximizing the complexity of the amorphous structure for an Icosahedral quenched-in nuclei quasi-crystal cluster to be formed in the amorphous matrix through the composition limitation and additive element control of Zr—Cu—Ni—Al alloy.

Abstract: Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

Abstract: Methods, compositions, and devices for transdermally administering an active agent such as donepezil are provided. In one aspect, the method comprises contacting skin with a transdermal device designed to create a depot of the active agent in the subject, removing the transdermal device and continuing to administer the active agent for a period after the device is removed.

Abstract: The present invention relates to a catalyst composition containing: one or more selected from the group consisting of a transition metal compound represented by Formula 1 and a transition metal compound represented by Formula 3, and dialkyl L-tartrate; a cleaning liquid composition containing the catalyst composition; and a method of cleaning a polymerization apparatus using the cleaning liquid composition, wherein all the variables are described herein.

Abstract: The present invention relates to a core-shell network structure formed using a biocompatible biopolymer and to a composition comprising same. Said structure can be used as an alternative to synthetic chemical materials, such as polyethylene glycol (PEG), to effectively disperse an insoluble effective substance within a composition, thus addressing safety issues, and formulations can be preserved stably for a long time through said network structure. Furthermore, said structure and the composition comprising same may provide useful benefits for the skin in terms of skin barrier enhancement, skin moisturization, skin regeneration, or the like.

Abstract: Methods, compositions, and devices for transdermally administering an active agent such as donepezil are provided.

Abstract: A transdermal delivery system is described, where the system comprises a drug reservoir layer comprising an active agent and a skin contact adhesive layer. A microporous membrane that has been pretreated with a membrane treatment composition before the membrane is incorporated into the system is disposed between the drug reservoir layer and the skin contact adhesive layer.

Abstract: In the present specification, a composition for improving skin transparency and a composition for reducing skin dullness are disclosed. The composition contains a mixed extract of Rosa multiflorae Fructus, black sesame, plum, quince, and pine nut as an active ingredient, wherein the Rosa multiflorae Fructus and black sesame may be germinated. Also, the composition has the effect of improving skin that has become dull due to the effects of aging, the external environment, stress, etc., so that the skin is made clear and transparent.

Abstract: The present invention relates to a pharmaceutical composition, quasi-drug, and food composition for preventing, ameliorating, or treating steatohepatitis, comprising a curcumin derivative and a TGF-? receptor inhibitor as active ingredients. In the composition, the TGF-? receptor inhibitor inhibits fibrosis of liver tissues, the curcumin derivative inhibits adipogenesis of hepatocyte increased during fibrosis inhibition process. Thus, compared to when a curcumin derivative or a TGF-? receptor inhibitor is administered alone as in the conventional cases, the composition exhibits an excellent effect of preventing and treating steatohepatitis, and therefore, can be used as a pharmaceutical composition, quasi-drug, and food composition for preventing, ameliorating, or treating metabolic liver diseases, including steatohepatitis.

Abstract: The specification relates to an emulsion composition of a formulation that can stably comprise an active substance through a biomimetic structure and can effectively deliver the active substance into the skin. The disclosure uses biocompatible natural vegetable proteins and macromolecules to mimic plant seeds with components and form a morphologically simulated structure of stem cells, so that various efficacious substances can be stably comprised in a high content in the formulation, and high skin absorbability of active substances can be provided. Accordingly, the disclosure can not only solve the safety issues caused by the use of conventional synthetic chemicals, but also enhance the effect of a cosmetic composition or pharmaceutical composition comprising an active substance by stabilizing the active substance in a formulation and effectively absorbing the active substance into the skin.

Abstract: Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

Abstract: Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

Abstract: An adhesive matrix and adhesive formulation are described. The adhesive matrix is comprised of a hydrophilic domain and a hydrophobic domain, and a therapeutically active agent contained in the matrix in a supersaturated, stable, condition. The hydrophilic domain and the hydrophobic domain are co-soluble in a solvent system, to provide a homogeneous blend in which the active agent is solubilized. The proportion of the hydrophilic domain and hydrophobic domain is selected to optimize, or maximize, solubility of active agent in the matrix.

Abstract: A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.

Abstract: The present disclosure provides a transdermal delivery system for treating Alzheimer’s disease with donepezil, optionally in combination with a second therapeutic agent such as aducanumab.